Compare AVD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVD | SPRO |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 71.0M |
| IPO Year | 1995 | 2017 |
| Metric | AVD | SPRO |
|---|---|---|
| Price | $2.13 | $1.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 209.7K | ★ 338.4K |
| Earning Date | 03-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.11 | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $515,114,000.00 | $66,802,000.00 |
| Revenue This Year | $8.82 | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $2.03 | $1.08 |
| 52 Week High | $5.92 | $3.08 |
| Indicator | AVD | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 33.48 |
| Support Level | $2.03 | $1.08 |
| Resistance Level | $2.43 | $1.29 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.87 | 18.01 |
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.